123 related articles for article (PubMed ID: 21838595)
1. Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats.
Lee KR; Chae YJ; Koo TS
Xenobiotica; 2011 Dec; 41(12):1100-7. PubMed ID: 21838595
[TBL] [Abstract][Full Text] [Related]
2. Quantification of lurasidone, an atypical antipsychotic drug, in rat plasma with high-performance liquid chromatography with tandem mass spectrometry.
Koo TS; Kim SJ; Lee J; Ha DJ; Baek M; Moon H
Biomed Chromatogr; 2011 Dec; 25(12):1389-94. PubMed ID: 21387355
[TBL] [Abstract][Full Text] [Related]
3. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.
Citrome L
Int J Clin Pract; 2011 Feb; 65(2):189-210. PubMed ID: 21129135
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, brain distribution, and plasma protein binding of the antiepileptic drug lacosamide in rats.
Koo TS; Kim SJ; Ha DJ; Baek M; Moon H
Arch Pharm Res; 2011 Dec; 34(12):2059-64. PubMed ID: 22210031
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of enzalutamide, an anti-prostate cancer drug, in rats.
Kim TH; Jeong JW; Song JH; Lee KR; Ahn S; Ahn SH; Kim S; Koo TS
Arch Pharm Res; 2015 Nov; 38(11):2076-82. PubMed ID: 25956695
[TBL] [Abstract][Full Text] [Related]
6. Lurasidone drug-drug interaction studies: a comprehensive review.
Chiu YY; Ereshefsky L; Preskorn SH; Poola N; Loebel A
Drug Metabol Drug Interact; 2014; 29(3):191-202. PubMed ID: 24825095
[TBL] [Abstract][Full Text] [Related]
7. Absorption, distribution, metabolism and excretion of telmesteine, a mucolitic agent, in rat.
Lee J; Son J; Rhee SW; Kim DH
Xenobiotica; 2003 Jul; 33(7):755-65. PubMed ID: 12893524
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and disposition of L-692,429. A novel nonpeptidyl growth hormone secretagogue in preclinical species.
Leung KH; Cohn DA; Miller RR; Doss GA; Stearns RA; Simpson RE; Feeney WP; Chiu SH
Drug Metab Dispos; 1996 Jul; 24(7):753-60. PubMed ID: 8818572
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
[TBL] [Abstract][Full Text] [Related]
10. Binding of lurasidone, a novel antipsychotic, to rat 5-HT7 receptor: analysis by [3H]SB-269970 autoradiography.
Horisawa T; Ishiyama T; Ono M; Ishibashi T; Taiji M
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():132-7. PubMed ID: 23367506
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, protein binding and metabolic profile of 3H-icometasone enbutate following intravenous, oral and intratracheal administrations to Sprague-Dawley rats.
Duchêne P; Giudicelli MD; Neau B; Gronfier A; Firmin Y; Villax P; Saivin S; Houin G
Arzneimittelforschung; 1998 Apr; 48(4):371-8. PubMed ID: 9608879
[TBL] [Abstract][Full Text] [Related]
12. Stability, blood partition, and pharmacokinetics of a new reversible proton pump inhibitor, YJA-20379-1.
Kim SH; Han KS; Choi WS; Chang MS; Lee MG
Res Commun Mol Pathol Pharmacol; 1997 Oct; 98(1):77-84. PubMed ID: 9434317
[TBL] [Abstract][Full Text] [Related]
13. Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studies.
Preskorn S; Ereshefsky L; Chiu YY; Poola N; Loebel A
Hum Psychopharmacol; 2013 Sep; 28(5):495-505. PubMed ID: 24014143
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, blood partition and protein binding of DA-7867, a new oxazolidinone.
Bae SK; Chung WS; Kim EJ; Rhee JK; Kwon JW; Kim WB; Lee MG
Biopharm Drug Dispos; 2004 Apr; 25(3):127-35. PubMed ID: 15083501
[TBL] [Abstract][Full Text] [Related]
15. Single dose pharmacokinetics and bioavailability of glucosamine in the rat.
Aghazadeh-Habashi A; Sattari S; Pasutto F; Jamali F
J Pharm Pharm Sci; 2002; 5(2):181-4. PubMed ID: 12207871
[TBL] [Abstract][Full Text] [Related]
16. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test.
Ishiyama T; Tokuda K; Ishibashi T; Ito A; Toma S; Ohno Y
Eur J Pharmacol; 2007 Oct; 572(2-3):160-70. PubMed ID: 17662268
[TBL] [Abstract][Full Text] [Related]
17. Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic.
Citrome L
Clin Schizophr Relat Psychoses; 2011 Jan; 4(4):251-7. PubMed ID: 21177242
[TBL] [Abstract][Full Text] [Related]
18. Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats.
Aravagiri M; Marder SR
Psychopharmacology (Berl); 2002 Feb; 159(4):424-31. PubMed ID: 11823895
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of ebrotidine in rats and dogs.
Albet C; Pérez JA; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):483-5. PubMed ID: 9205748
[TBL] [Abstract][Full Text] [Related]
20. Anatomical specificity in the modulation of activity-regulated genes after acute or chronic lurasidone treatment.
Luoni A; Rocha FF; Riva MA
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Apr; 50():94-101. PubMed ID: 24361635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
